Pressure BioSciences Announces First Sale of Barozyme™ HT48 and Accelerated Marketing

Posted by Laura Swartz

February 10, 2015 at 11:46 AM

This morning, laboratory instrumentation company Pressure BioSciences, Inc. (PBIO-OTC) announced that it had received the first purchase order for one of its newest products, the Barozyme™ HT48 High-throughput System, and had the potential for a second order for the same product. The possible second purchase could come from an existing European customer that has requested a quote.
 
About the Barozyme™ HT48

Read More

Topics: Pressure BioSciences

Pressure BioSciences Reports a YTD Sales Increase of 45%

Posted by Laura Swartz

November 18, 2014 at 10:15 AM

Pressure BioSciences, Inc. (PBIO-OTC) has reported its financial results for the third quarter 2014 and year-to-date period ended September 30th. Highlights of these results are an increase in products and services revenue of 14% for the third quarter, while operating loss continues to narrow. Year to date, the company reported products and services revenue up 45% and sales of consumables up 48%, which almost entirely offset the loss in grant revenue.

Read More

Topics: Pressure BioSciences

New Method to Improve Drug Discovery and Design Hinges on PCT

Posted by Laura Swartz

October 27, 2014 at 2:10 PM

Pressure BioSciences, Inc. (PBIO-OTC) reported this morning that it has received an important third-party validation of the protein analysis possibilities enabled by its proprietary pressure cycling technology (PCT). Earlier this month, at the 13th Human Proteome Organization World Congress in Madrid, Spain, renowned protein scientist Professor Ruedi Aebersold from ETH Zurich and the University of Zurich combined PCT with AB SCIEX’s SWATH mass spectrometry method, and was able to analyze thousands of proteins by mass spectrometry on small, needle biopsy samples. In presenting his process and findings, Dr. Aebersold noted that prior to the combination of the mass spectrometry method with Pressure BioSciences’ PCT platform, it had been nearly impossible to accomplish the quantification of thousands of proteins in needle biopsy samples.

Read More

Topics: Pressure BioSciences

Pressure BioSciences Partners With Powertech for Chinese Sales

Posted by Laura Swartz

October 20, 2014 at 10:45 AM

Laboratory instrumentation company Pressure BioSciences, Inc. (PBIO-OTC) announced this morning that it had entered into an exclusive, three-year distribution agreement with a Chinese distributor of analytical instruments and other equipment to China's biotech, pharma, agricultural, environmental, food safety, and commercial laboratory markets. Pressure BioSciences reports that the company, Powertech Technology Company Ltd., is a recognized distributor to the Chinese market, with a network of 18 distribution offices, a maintenance center, an applications laboratory, and multiple sub-dealers. The press release further stated that Powertech's current business partners aside from Pressure BioSciences include Dupont, GE Healthcare, Sartorius, Zeiss, and Agilent.

Read More

Topics: Pressure BioSciences

NEW RESEARCH: Pressure BioSciences On the Move

Posted by Laura Swartz

September 29, 2014 at 9:56 AM

This morning we published a 16-page Quarterly Update on laboratory instrumentation company, Pressure BioSciences, Inc. (PBIO-OTC). 

Read More

Topics: Pressure BioSciences

Dial-in Info for Investor Conference Call with Pressure BioSciences, Inc. ($PBIO)

Posted by Laura Swartz

August 13, 2014 at 11:39 AM

Pressure BioSciences, Inc. (PBIO-OTC), a company that develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6 billion life sciences sample preparation market, will hold a conference call to update investors on its business and financial results on Thursday, August 14, 2014. The call will cover the company's financial results for the second quarter 2014.

Read More

Topics: Pressure BioSciences

Pressure BioSciences (PBIO) to Consider Strategic Financing and Spin-off Options

Posted by Laura Swartz

June 26, 2014 at 4:33 PM

Today Pressure BioSciences, Inc. (PBIO-OTC) announced a relationship with IssuWorks, a company that strives to provide services and technology to improve capital formation, distribution, and aftermarket results for issuers, investors, and investment banks. Pressure BioSciences has retained IssuWorks and its management team to review the Company’s strategic and financing alternatives, including the possible spin-off of vertical market applications into new, stand-alone businesses.

Read More

Topics: Pressure BioSciences

NEW RESEARCH: 12-page Quarterly Update Available on Pressure BioSciences (PBIO)

Posted by Laura Swartz

June 16, 2014 at 4:58 PM

This afternoon, we published an update on Pressure BioSciences, Inc. (PBIO-OTC), a company focused on the development and commercialization of proprietary laboratory instruments and consumable products. The update covers the company's most recently reported financial results for the first quarter 2014 and highlights from fiscal year 2013, as well as describes new product introductions, including a new pressure cycling technology (PCT) platform being introduced this week at the annual meeting of the American Society for Mass Spectrometry.

Read More

Topics: Pressure BioSciences

Pressure BioSciences, Inc. (PBIO) Reports Fourth Quarter and Fiscal Year 2013 Financial Results

Posted by Samy Goldfarb

April 2, 2014 at 12:15 PM

Pressure BioSciences, Inc. (PBIO-OTC), a company that develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6 billion life sciences sample preparation market, announced financial results for the three-month period and fiscal year ended December 31, 2013, and provided a business update.

Read More

Topics: Pressure BioSciences

An Introduction to the Sample Preparation Life Science Research Market

Posted by Laura Swartz

February 10, 2014 at 10:28 AM

Upon news that over the past two months, Massachusetts-based Pressure BioSciences, Inc. (PBIO-OTC) has raised an excess of $2.2 million, and seeks to raise more in February 2014, it is time to look closer at the business of this small-cap company. A quick Google search will tell you that Pressure BioSciences makes laboratory instruments for the “sample preparation” market—a market that is integral to life science research in tens of thousands of laboratories worldwide. But what is sample preparation? Is there a market for Pressure BioSciences’ products?

What is Sample Preparation?

Read More

Topics: Pressure BioSciences

PBIO: Investor Call with Merriman Capital on Thurs., Dec. 12 at 4:30p

Posted by Laura Swartz

December 11, 2013 at 9:06 PM

On Thursday, December 12th, Merriman Capital, Inc. will host an investor call for Pressure BioSciences, Inc. (PBIO) at 4:30 p.m. EST. Investors and any other interested parties should dial into this call for an update on PBIO’s recent achievements, such as the Company’s record revenue in the third quarter 2013, and forthcoming milestones. A Q&A session will also be available following the call. Pressure BioSciences’ CEO Richard T. Schumacher, Board Chairman Jeffrey N. Peterson, and other board members Mr. Vito Mangiardi, Mr. Kevin Pollack, and Dr. Mickey Urdea will join in the Q&A.  

Conference Call Details

Read More

Topics: Pressure BioSciences

Record Revenue and More Products to Come from Pressure BioSciences

Posted by Laura Swartz

November 19, 2013 at 11:37 AM

One of the newest companies in our coverage universe, Pressure BioSciences, Inc. (PBIO-OTC), holds exciting new technologies for life science research—technologies that could help advance the work being done in tens of thousands of laboratories worldwide. The Company’s pressure cycling technology (PCT) platform, which is able to apply and release high levels of hydrostatic pressure in a safe and controlled manner, aids researchers and scientists by giving them the laboratory equipment needed to improve the processing of samples—which ultimately can lead to higher-quality research in critical fields like testing cancer therapies, creating new vaccines, and even faster and more accurate DNA analysis for things like processing rape kits. As an indication of the competitive advantage in research that Pressure BioSciences’ products can offer, to the Company’s knowledge, PCT has been shown to be the only technology able to completely kill anthrax while still leaving the sample in a testable state.  

Having demonstrated the utility of its equipment through roughly 235 installations in 150 marquee laboratories around the world, the industry is starting to take notice of the small-cap Pressure BioSciences, and with good reason.  

Read More

Topics: Pressure BioSciences

NEW RESEARCH: Innovations in Life Science Research with $PBIO

Posted by Laura Swartz

November 3, 2013 at 11:31 PM

We are pleased to announce the publication of an Executive Informational Overview (EIO) on Pressure BioSciences, Inc. (PBIO-OTC), a company developing and commercializing proprietary laboratory instruments and consumable products. The full 76-page report is available for download here.

Read More

Topics: Pressure BioSciences

Receive Our Research Notifications

About This Blog

We provide investor-based research and corporate communications services to companies worldwide. Visit our About Us page to learn more.

Posts by Topic